0000000000949320

AUTHOR

Siegfried Hagl

showing 1 related works from this author

Bridge to Operation with the GPIIb/IIIa Inhibitor Abciximab in High-Risk Coronary Patients

2006

BACKGROUND Glycoprotein-IIb/IIIa inhibitors are now frequently used in the cardiological treatment of high-risk coronary patients even if the patient is considered suitable for surgical intervention. However, there is no consensus whether GPIIb/IIIa inhibitors should be stopped before operation because of an increased risk of bleeding or if surgery should even be delayed until the anticoagulating effect subsides. METHODS From June 2002 to August 2003 140 patients who had to undergo primary aorto-coronary bypass for ongoing myocardial ischemia were enrolled in the present study. The patients received either clopidogrel, aspirin and heparin or additionally abciximab until operation. RESULTS A…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyAbciximabMyocardial InfarctionHemodynamicsCoronary DiseasePlatelet Glycoprotein GPIIb-IIIa ComplexImmunoglobulin Fab FragmentsGpIIb/IIIaRisk FactorsInternal medicinemedicineAbciximabHumansProspective StudiesRegistriesCoronary Artery BypassAgedAspirinbusiness.industryIncidence (epidemiology)Antibodies MonoclonalHeparinMiddle AgedClopidogrelSurvival AnalysisHemostasis SurgicalTreatment OutcomeBridge (graph theory)Elective Surgical ProceduresCardiologyFemaleSurgeryCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation InhibitorsFollow-Up Studiesmedicine.drugThe Thoracic and Cardiovascular Surgeon
researchProduct